Stocktoria

BriaCell Therapeutics Corp. BCTX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2006-10-12 · LEI

BriaCell Therapeutics Corp. statistics & valuation

Market cap$38.5M
P / B2.2×
Return on equity-151.8%
Return on capital-153.9%

Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20212022202320242025
Operating margin (%)
20212022202320242025
Return on equity (%)
-49.90% -259.80% -151.80% 20212022202320242025
Shares outstanding
15.3M 15.5M 16.0M 121907 1.9M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-23.80% -63.00% -74.70% -81.60% -121.50% 20212022202320242025
Free cash flow margin (%)
20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$1.73 -$1.30 -$43.68 -$62.19 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Return on assets-121.5%-81.6%-74.7%-63.0%-23.8%
Return on equity-151.8%178.5%537.5%-259.8%-49.9%
Current ratio5.010.4914.9645.00103.81

Computed from company filings · US · as of 2025-07-31. Facts plus Stocktoria's own computed scores — not investment advice.